New Chipotle restaurant brings 30 job openings to growing St. Cloud community
Chipotle Mexican Grill Inc. (NYSE: CMG) opened the doors of its second St. Cloud restaurant on March 31.
Chipotle is currently hiring at the new St. Cloud location, with approximately 30 job openings available. The restaurant operates daily from 10:45 a.m. to 10:00 p.m.
Located at 890 E. Irlo Bronson Memorial Hwy. in St. Cloud, the eatery is in a new multi-tenant commercial building. The property was purchased by Apopka-based Hanlex Development LLC in 2017 for $425,000.
Click here to read the full story on the Orlando Business Journal's website.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
30 minutes ago
- Epoch Times
The Hidden Math That Makes Some Australians Poorer for Working Harder
AD It may seem counterintuitive, but working longer hours can make you less money, the e61 Institute says. A pile of bills in Brisbane, Australia, on Oct. 30, 2013. AAP Image/Dan Peled 8/13/2025 | Updated: 8/13/2025 Not so long ago, working harder was thought to guarantee you were better off. Rex Widerstrom is a New Zealand-based reporter with over 40 years of experience in media, including radio and print. He is currently a presenter for Hutt Radio. Author's Selected Articles
Business Upturn
33 minutes ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
an hour ago
- Yahoo
Citi Upgrades Invitation Homes (INVH) to Buy from Neutral
Invitation Homes Inc. (NYSE:INVH) is one of the best residential REITs to buy. On June 6, Citi upgraded INVH to Buy, and trimmed American Homes 4 Rent (NYSE:AMH) to Neutral, based on relative value and the view that Invitation Homes' financial performance is expected to catch up to its competitor. According to Citi, INVH's recent 6% underperformance compared to American Homes 4 Rent has increased the valuation difference, presenting an attractive buying opportunity. Citi observed that INVH trades at a cap rate approximately 30 basis points below AMH's, placing it near the historically lowest spread levels. A contemporary single-family house at dusk in a residential neighborhood. The analysts commented that Invitation Homes Inc. (NYSE:INVH) is in a strong position to handle these risks because it knows the build-to-rent (BTR) market well, including rent prices and property values. They also mentioned that the company's outlook seems cautious, which means it might actually do better than expected when it comes to occupancy and rent growth. Shop Top Mortgage Rates Your Path to Homeownership A quicker path to financial freedom Personalized rates in minutes The firm sees more upside potential from INVH's lending strategy, estimating it could lift yearly earnings by 7 cents, which is an increase of about 3.5% over the coming years. The program also increases the potential to secure built-to-rent assets from residential developers. Citi believes both Invitation Homes and American Homes 4 Rent will keep growing rents by around 4% in the next few years, even though lease growth has slowed down recently. While AMH might have already hit its peak in new lease growth in May, Citi says the differences between the two companies are small and probably just because of how the data is measured or seasonal changes. Invitation Homes Inc. (NYSE:INVH) is a major American REIT that focuses on single-family homes. It provides modern houses in good locations, close to jobs and schools. While we acknowledge the potential of INVH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
